294 related articles for article (PubMed ID: 30317101)
1. Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders - Results from a double-blind, randomized and placebo-controlled clinical trial.
Jahangard L; Sadeghi A; Ahmadpanah M; Holsboer-Trachsler E; Sadeghi Bahmani D; Haghighi M; Brand S
J Psychiatr Res; 2018 Dec; 107():48-56. PubMed ID: 30317101
[TBL] [Abstract][Full Text] [Related]
2. Omega-3-polyunsatured fatty acids (O3PUFAs), compared to placebo, reduced symptoms of occupational burnout and lowered morning cortisol secretion.
Jahangard L; Hedayati M; Abbasalipourkabir R; Haghighi M; Ahmadpanah M; Faryadras M; Mikoteit T; Sadeghi Bahmani D; Brand S
Psychoneuroendocrinology; 2019 Nov; 109():104384. PubMed ID: 31382171
[TBL] [Abstract][Full Text] [Related]
3. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
4. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
da Silva TM; Munhoz RP; Alvarez C; Naliwaiko K; Kiss A; Andreatini R; Ferraz AC
J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
[TBL] [Abstract][Full Text] [Related]
5. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
[TBL] [Abstract][Full Text] [Related]
6. In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder.
Haghighi M; Khodakarami S; Jahangard L; Ahmadpanah M; Bajoghli H; Holsboer-Trachsler E; Brand S
J Psychiatr Res; 2014 Nov; 58():109-14. PubMed ID: 25130678
[TBL] [Abstract][Full Text] [Related]
7. Effects of Aphrodite (an Herbal Compound) on SSRI-Induced Sexual Dysfunctions and Depression in Females with Major Depressive Disorder: Findings from a Randomized Clinical Trial.
Shahmoradi N; Davarinejad O; Brühl AB; Brand S
Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763782
[No Abstract] [Full Text] [Related]
8. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial.
Lespérance F; Frasure-Smith N; St-André E; Turecki G; Lespérance P; Wisniewski SR
J Clin Psychiatry; 2011 Aug; 72(8):1054-62. PubMed ID: 20584525
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial.
Ghaleiha A; Davari H; Jahangard L; Haghighi M; Ahmadpanah M; Seifrabie MA; Bajoghli H; Holsboer-Trachsler E; Brand S
Eur Arch Psychiatry Clin Neurosci; 2016 Dec; 266(8):695-702. PubMed ID: 26984349
[TBL] [Abstract][Full Text] [Related]
10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
11. Effect of Omega-3 Fatty Acids on Depressive Symptoms in HIV-Positive Individuals: A Randomized, Placebo-Controlled Clinical Trial.
Ravi S; Khalili H; Abbasian L; Arbabi M; Ghaeli P
Ann Pharmacother; 2016 Oct; 50(10):797-807. PubMed ID: 27323793
[TBL] [Abstract][Full Text] [Related]
12. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
Munizza C; Olivieri L; Di Loreto G; Dionisio P
Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
[TBL] [Abstract][Full Text] [Related]
14. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
16. Influence of adjuvant clonidine on mania, sleep disturbances and cognitive performance - Results from a double-blind and placebo-controlled randomized study in individuals with bipolar I disorder during their manic phase.
Ahmadpanah M; Pezeshki R; Soltanian AR; Jahangard L; Dürsteler KM; Keshavarzi A; Brand S
J Psychiatr Res; 2022 Feb; 146():163-171. PubMed ID: 34990968
[TBL] [Abstract][Full Text] [Related]
17. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
20. Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements.
Carney RM; Steinmeyer BC; Freedland KE; Rubin EH; Rich MW; Harris WS
J Clin Psychiatry; 2016 Feb; 77(2):e138-43. PubMed ID: 26930527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
